Natera, Inc. (NTRA)

NASDAQ: NTRA · Real-Time Price · USD
167.35
+7.14 (4.46%)
At close: Oct 3, 2025, 4:00 PM EDT
167.72
+0.37 (0.22%)
Pre-market: Oct 6, 2025, 8:40 AM EDT
4.46%
Market Cap22.97B
Revenue (ttm)1.96B
Net Income (ttm)-253.24M
Shares Out 137.25M
EPS (ttm)-1.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,145,532
Open161.54
Previous Close160.21
Day's Range160.59 - 167.91
52-Week Range117.27 - 183.00
Beta1.74
AnalystsStrong Buy
Price Target192.41 (+14.98%)
Earnings DateNov 11, 2025

About NTRA

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissu... [Read more]

Sector Healthcare
IPO Date Jul 2, 2015
Employees 4,434
Stock Exchange NASDAQ
Ticker Symbol NTRA
Full Company Profile

Financial Performance

In 2024, Natera's revenue was $1.70 billion, an increase of 56.75% compared to the previous year's $1.08 billion. Losses were -$190.43 million, -56.20% less than in 2023.

Financial Statements

Analyst Summary

According to 17 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $192.41, which is an increase of 14.98% from the latest price.

Price Target
$192.41
(14.98% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPT

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a milestone in the EXPAND trial with the enrollmen...

5 days ago - Business Wire

Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a peer-reviewed manuscript in the Journal of Cl...

6 days ago - Business Wire

Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology...

7 days ago - Business Wire

Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Natera, Inc. (NASDAQ:NTRA) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 10:30 AM EDT Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Ev...

11 days ago - Seeking Alpha

Can Natera Stock Reach $500?

Let's start with something remarkable. Natera (NASDAQ: NTRA) just marked its 10th anniversary as a public company, and what a journey it has been.

20 days ago - Forbes

Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript

Natera, Inc. (NASDAQ:NTRA) Baird Global Healthcare Conference 2025 September 9, 2025 8:30 AM EDT Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Conference C...

25 days ago - Seeking Alpha

Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability

For my first rating of Natera, I called it a buy, while today's consensus seems to be between a hold and a strong buy. Both proven revenue growth and expected future growth outlooks are upside drivers...

4 weeks ago - Seeking Alpha

Natera Provides Update on Patent Litigation with NeoGenomics

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGe...

5 weeks ago - Business Wire

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ra...

5 weeks ago - Business Wire

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Associatio...

6 weeks ago - Business Wire

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers feat...

6 weeks ago - Business Wire

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These ...

6 weeks ago - Business Wire

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011...

7 weeks ago - Business Wire

Natera shares surge 17% after strong Q2 results and upgraded guidance

Shares of genetic testing company Natera (NASDAQ:NTRA) jumped sharply in morning trading, rising as much as 17% after the company reported better-than-expected second-quarter 2025 financial results an...

2 months ago - Invezz

Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript

Natera, Inc. (NASDAQ:NTRA) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Michael B. Brophy - Chief Fi...

2 months ago - Seeking Alpha

Natera Reports Second Quarter 2025 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. R...

2 months ago - Business Wire

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal ...

2 months ago - Business Wire

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present several new datasets at the 2025 World Transp...

2 months ago - Business Wire

Natera to Report Its Second Quarter Results on August 7, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30,...

2 months ago - Business Wire

Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization...

2 months ago - Business Wire

PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published fin...

2 months ago - Business Wire

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latit...

3 months ago - Business Wire

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical...

3 months ago - Business Wire

Natera Announces Medicare Coverage for Signatera™ Genome

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medica...

4 months ago - Business Wire

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assa...

4 months ago - Business Wire